News
RNA
7.57
-4.96%
-0.40
Weekly Report: what happened at RNA last week (1102-1106)?
Weekly Report · 3d ago
Atrium Therapeutics To Present New Nonclinical Data On ATR 1072 For Potential Treatment Of PRKAG2 At The American Heart Association Scientific Sessions On November 6; ATR 1072 Impacted Key Characteristics Of PRKAG2, Including Accumulation Of Cardiac Glycogen And Cardiac Hypertrophy
Benzinga · 11/02 11:35
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
PR Newswire · 11/02 11:30
Weekly Report: what happened at RNA last week (1026-1030)?
Weekly Report · 11/02 10:31
Atrium Therapeutics Price Target Cut to $20.00/Share From $25.00 by HC Wainwright & Co.
Dow Jones · 10/28 11:52
Atrium Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 10/28 11:52
HC Wainwright & Co. Maintains Buy on Atrium Therapeutics, Lowers Price Target to $20
Benzinga · 10/28 11:42
Atrium Therapeutics price target lowered to $20 from $25 at H.C. Wainwright
TipRanks · 10/28 10:16
Atrium Therapeutics doses first patient in Corventis clinical trial
TipRanks · 10/27 10:50
Atrium Therapeutics Doses First Patient In Its Phase 1/2 Corventis Clinical Trial Evaluating ATR 1072 For Potential Treatment Of PRKAG2 Syndrome; Expects Initial Proof-Of-Concept Data In H2 2027
Benzinga · 10/27 10:38
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
PR Newswire · 10/27 10:30
Weekly Report: what happened at RNA last week (1019-1023)?
Weekly Report · 10/26 10:30
This Constellation Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 10/22 13:19
Atrium Therapeutics Price Target Announced at $15.00/Share by Roth Capital
Dow Jones · 10/22 10:52
Roth Capital Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $15
Benzinga · 10/22 10:42
Atrium Therapeutics initiated with a Buy at Roth Capital
TipRanks · 10/22 08:30
Shareholder Yakira Capital Urges Atrium Therapeutics To Explore Strategic Sale Or Partnerships, Citing 44% Stock Decline, $50M Dilutive Financing
Benzinga · 10/20 12:12
Weekly Report: what happened at RNA last week (1012-1016)?
Weekly Report · 10/19 10:30
Cantor Fitzgerald Reaffirms Their Buy Rating on Atrium Therapeutics, Inc. (RNA)
TipRanks · 10/15 11:56
Weekly Report: what happened at RNA last week (1005-1009)?
Weekly Report · 10/12 10:37
More
Webull provides a variety of real-time RNA stock news. You can receive the latest news about Atrium Therapeutics, Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNA
Atrium Therapeutics, Inc. is a biopharmaceutical company engaged in the delivery of ribonucleic acid (RNA) therapeutics for people living with cardiomyopathy. Its technology leverages the targeted RNA delivery platform, which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with oligonucleotides. It is designed to allow selective targeting of the underlying genetic drivers of disease. Its development pipeline consists of programs that target genetically validated drivers of cardiomyopathy, which include Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) and Phospholamban (PLN). Its genetic drivers are associated with PRKAG2 syndrome and PLN cardiomyopathy, which is a genetic heart condition associated with life-threatening forms of heart disease. Its programs are supported by preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform technology.